MAS1 and type 1 diabetes mellitus: These findings have important implications to the therapeutic efficacy of Mas agonists on attenuating vascular dysfunctions and complications, since we showed that the activation of Mas receptors triggers a positive feedback over the ACE2-angiotensin-(1–7)-Mas axis when the functionality of this vasoprotective axis is impaired, even during diseases that subregulate the vascular expression of these receptors, such as type I-diabetes.